Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
Clinical trial NCT03020199 · COMPLETED
Trial details
- NCT number
- NCT03020199
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-27
- Primary completion
- 2021-11-30
- Enrollment
- 196
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.